Drugs / CM-24
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02346955 | Feb 2015 → Feb 2017 | colorectal cancer, gastric cancer, melanoma, non-small cell lung carcinoma +2 | Famewave Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04731467 | Mar 2021 → Sep 2024 | colorectal adenocarcinoma, malignant pancreatic neoplasm, melanoma, non-small cell lung carcinoma +2 | Famewave Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-27 | Purple Biotech Ltd. | Results Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit purple-biotech.com ↗
These results suggest that serum MPO may be a predictive biomarker for survival in the CM24+Nivolumab + Nal-IRI/5FU/LV arm. |
| 2020-05-14 | Purple Biotech Ltd. | Results Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program purple-biotech.com ↗
CM-24 was found to be safe and well-tolerated in all patients, with no discontinuations of study drug or dose limiting toxicities (up to 10mg/kg). |
All press releases naming this drug 4 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM24 | “Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors” NCT04731467 ↗ |
| Known as | MK-6018 | “Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine...” NCT02346955 ↗ |
| Modality | Monoclonal antibody | “humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1” NCT02346955 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT02346955 ↗ |
| Target | CEACAM1 | “humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1” NCT02346955 ↗ |